ARTV vs TGT · $37.3M cap vs P/E 17, rev $51.98B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
ARTV currently screens at market cap $37.3M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the ARTV and TGT stock pages for the full models.
Not investment advice.